Business Context and Reporting Period
Palisade Bio, Inc. (PALI) filed a Form 8-K on October 21, 2025, reporting events occurring between September 4, 2025, and October 22, 2025. The filing addresses corporate governance and executive compensation matters rather than operational or financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the administration of a specific equity compensation plan.
Material Changes
- Phantom Equity Plan Termination: The Board of Directors approved the termination of the Phantom Unit Plan on October 22, 2025.
- Forfeiture of Awards: Unvested Phantom Units granted to J.D. Finley (CEO), Mitchell Jones (CMO), and Ryker Willie (SVP of Finance) were terminated on the Termination Date for no consideration.
- Plan History: The Plan was originally adopted on September 4, 2025, and was active for approximately one month prior to termination.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the immediate loss of unvested equity compensation for the named executives due to the plan's termination.
Investor Verification Checklist
- Verify the total number of Phantom Units originally granted to the CEO, CMO, and SVP of Finance to assess the magnitude of the forfeited compensation.
- Confirm whether the termination of the Phantom Unit Plan impacts the company's ability to attract or retain key personnel.
- Review subsequent filings to determine if a new equity incentive plan will be adopted to replace the terminated Plan.
- Check if the forfeiture of these units triggers any tax implications or accounting adjustments for the company.